Voranush Chongsrisawat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Voranush Chongsrisawat has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Yong Poovorawan
Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
16 shared publications - Apiradee Theamboonlers
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5 shared publications - Paisarn Vejchapipat
Department of Surgery, Faculty of Medicine, Chulalongkorn University & King Chulalongkorn Memorial Hospital
5 shared publications Sittichoke Prachuapthunyachart
4 shared publicationsNutchanart Thawornsuk
Department of Biochemistry, 2Center of Excellence in Viral Hepatitis Research, Department of Pediatrics and 3Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3 shared publicationsPalittiya Sintusek
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
3 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 15 (1)
Clinical outcomes of two lactose-free formulas in the management of acute childhood diarrhea
BACKGROUND Acute diarrhea is the most common gastrointestinal disease in children under five years of age and is associated with significant morbidity and mortality risks. Lactose-free formulas may be beneficial for hospitalized patients. AIM To compare the efficacy, safety, and cost-effectiveness of a medium-chain triglyceride-containing lactose-free formula (MLF) with a standard lactose-free formula (SLF) in children hospitalized with acute diarrhea. METHODS In this randomized, double-blind, controlled trial, children aged 6-24 months were randomized to receive MLF or SLF. The primary outcomes were the duration until diarrhea resolution and the frequency of stools after enrollment. Secondary outcomes included length of hospital stay, treatment costs, and caregiver satisfaction. RESULTS Forty-four children completed the study (MLF = 22, SLF = 22). The median duration of diarrhea after enrollment did not differ significantly between the groups, 24.0 hours [interquartile range (IQR): 21.5] vs 45.0 hours (IQR: 49.0); P = 0.293. The reduction in stool frequency was also comparable [7.5 (IQR: 5.8) vs 4.0 (IQR: 3.8) times/day; P = 0.083]. The Hodges-Lehmann estimated median difference in diarrhea duration was -4 hours (95% confidence interval: -26.0 to 2.0), supporting the noninferiority of MLF. The median length of hospital stay was 2 days in both groups. Formula costs were significantly lower in the MLF group (227.9 Thai Baht vs 373.6 Thai Baht; P < 0.001). Caregiver satisfaction, product acceptance, and safety profiles were comparable between the groups. CONCLUSION MLF demonstrated noninferior clinical outcomes and safety compared to SLF, with a significant reduction in formula-related costs. MLF could be an appropriate alternative for the management of acute diarrhea in young children, especially in resource-constrained settings.
- 9 March 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 15 (1)
Open AccessClinical outcomes of two lactose-free formulas in the management of acute childhood diarrhea
BACKGROUND Acute diarrhea is the most common gastrointestinal disease in children under five years of age and is associated with significant morbidity and mortality risks. Lactose-free formulas may be beneficial for hospitalized patients. AIM To compare the efficacy, safety, and cost-effectiveness of a medium-chain triglyceride-containing lactose-free formula (MLF) with a standard lactose-free formula (SLF) in children hospitalized with acute diarrhea. METHODS In this randomized, double-blind, controlled trial, children aged 6-24 months were randomized to receive MLF or SLF. The primary outcomes were the duration until diarrhea resolution and the frequency of stools after enrollment. Secondary outcomes included length of hospital stay, treatment costs, and caregiver satisfaction. RESULTS Forty-four children completed the study (MLF = 22, SLF = 22). The median duration of diarrhea after enrollment did not differ significantly between the groups, 24.0 hours [interquartile range (IQR): 21.5] vs 45.0 hours (IQR: 49.0); P = 0.293. The reduction in stool frequency was also comparable [7.5 (IQR: 5.8) vs 4.0 (IQR: 3.8) times/day; P = 0.083]. The Hodges-Lehmann estimated median difference in diarrhea duration was -4 hours (95% confidence interval: -26.0 to 2.0), supporting the noninferiority of MLF. The median length of hospital stay was 2 days in both groups. Formula costs were significantly lower in the MLF group (227.9 Thai Baht vs 373.6 Thai Baht; P < 0.001). Caregiver satisfaction, product acceptance, and safety profiles were comparable between the groups. CONCLUSION MLF demonstrated noninferior clinical outcomes and safety compared to SLF, with a significant reduction in formula-related costs. MLF could be an appropriate alternative for the management of acute diarrhea in young children, especially in resource-constrained settings.
- Open Access
- 1 January 2026
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 29 (5) , 390-400
Management of Acute Diarrhea in Children after Implementing the Thai Clinical Practice Guideline
Prachuapthunyachart S, et al. Pediatr Gastroenterol Hepatol Nutr. 2026 Sep;29(5):390-400. https://doi.org/10.5223/pghn.2026.29.5.390
- 1 January 2026
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 29 (5) , 390-400
Open AccessManagement of Acute Diarrhea in Children after Implementing the Thai Clinical Practice Guideline
Prachuapthunyachart S, et al. Pediatr Gastroenterol Hepatol Nutr. 2026 Sep;29(5):390-400. https://doi.org/10.5223/pghn.2026.29.5.390
- 21 August 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (6) , 769-775
Novel PLEC variants associated with infantile cholestasis
Plectin is a cytoskeletal linker of intermediate filaments, encoded by the PLEC gene. Recently, plectin mutations have been identified in a pair of siblings with progressive familial intrahepatic cholestasis. Here, we reported two unrelated infants with plectinopathy causing cholestatic jaundice with novel variants in the PLEC gene. Trio exome sequencing identified compound heterozygous variants in the PLEC gene for each patient: c.71‐11768C>T and c.4331G>T (p.Arg1444Leu) in Patient 1, and c.592C>T (p.Arg198Trp) and c.4322G>A (p.Arg1441His) in Patient 2. Immunofluorescence staining of liver samples from both patients revealed scattered signals of plectin in the cytoplasm of hepatocytes and reduced colocalization of plectin and cytokeratin 8. This study not only underscores the involvement of plectin in cholestasis but also highlights the utility of exome sequencing as a powerful diagnostic tool in identifying genetic underpinnings of infantile cholestasis.
- 21 August 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (6) , 769-775
Novel PLEC variants associated with infantile cholestasis
Plectin is a cytoskeletal linker of intermediate filaments, encoded by the PLEC gene. Recently, plectin mutations have been identified in a pair of siblings with progressive familial intrahepatic cholestasis. Here, we reported two unrelated infants with plectinopathy causing cholestatic jaundice with novel variants in the PLEC gene. Trio exome sequencing identified compound heterozygous variants in the PLEC gene for each patient: c.71‐11768C>T and c.4331G>T (p.Arg1444Leu) in Patient 1, and c.592C>T (p.Arg198Trp) and c.4322G>A (p.Arg1441His) in Patient 2. Immunofluorescence staining of liver samples from both patients revealed scattered signals of plectin in the cytoplasm of hepatocytes and reduced colocalization of plectin and cytokeratin 8. This study not only underscores the involvement of plectin in cholestasis but also highlights the utility of exome sequencing as a powerful diagnostic tool in identifying genetic underpinnings of infantile cholestasis.
- 5 February 2024
- Published by Wiley in Pediatric Anesthesia
- Vol. 34 (4) , 366-370
Changes in branched‐chain amino acids in an infant with maple syrup urine disease during perioperative pediatric liver transplant: A case report
An 11‐month‐old female infant diagnosed with classic subtype IB maple syrup urine disease underwent living donor liver transplantation. Blood samples for plasma amino acid analysis were collected during the three phases of the operation. Despite the perioperative prophylactic administration of 12.5% hypertonic dextrose solution with insulin and a 20% intralipid emulsion, the blood levels of the branched‐chain amino acids increased dramatically during surgery, consistent with an acute intraoperative metabolic decompensation. However, these blood levels normalized soon after liver transplantation with an excellent outcome. We suggest that the occurrence of an intraoperative metabolic crisis during liver transplantation is not necessarily a sign of graft failure.
- 5 February 2024
- Published by Wiley in Pediatric Anesthesia
- Vol. 34 (4) , 366-370
Changes in branched‐chain amino acids in an infant with maple syrup urine disease during perioperative pediatric liver transplant: A case report
An 11‐month‐old female infant diagnosed with classic subtype IB maple syrup urine disease underwent living donor liver transplantation. Blood samples for plasma amino acid analysis were collected during the three phases of the operation. Despite the perioperative prophylactic administration of 12.5% hypertonic dextrose solution with insulin and a 20% intralipid emulsion, the blood levels of the branched‐chain amino acids increased dramatically during surgery, consistent with an acute intraoperative metabolic decompensation. However, these blood levels normalized soon after liver transplantation with an excellent outcome. We suggest that the occurrence of an intraoperative metabolic crisis during liver transplantation is not necessarily a sign of graft failure.
- 17 November 2022
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 36 (1) , S239
Immunogenicity of an mRNA-based COVID-19 vaccine among adolescents with obesity or liver transplants
Chomchanat Tubjaroen, Sittichoke Prachuapthunyachart, Nattakoon Potjalongsilp, Pimpayao Sodsai, Peera Jaruampornpan, Voranush Chongsrisawat. Korean J Transplant 2022;36:239. https://doi.org/10.4285/ATW2022.F-3788
- 17 November 2022
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 36 (1) , S239
Immunogenicity of an mRNA-based COVID-19 vaccine among adolescents with obesity or liver transplants
Chomchanat Tubjaroen, Sittichoke Prachuapthunyachart, Nattakoon Potjalongsilp, Pimpayao Sodsai, Peera Jaruampornpan, Voranush Chongsrisawat. Korean J Transplant 2022;36:239. https://doi.org/10.4285/ATW2022.F-3788
- Open Access
Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants
There are limited data regarding the immunogenicity of mRNA-based SARS-CoV-2 vaccine BNT162b2 among immunosuppressed or obese adolescents. We evaluated the humoral immune response in adolescents with obesity and adolescent liver transplant recipients (LTRs) after receiving two BNT162b2 doses. Sixty-eight participants (44 males; mean age 14.9 ± 1.7 years), comprising 12 LTRs, 24 obese, and 32 healthy adolescents, were enrolled. Immunogenicity was evaluated by anti-SARS-CoV-2 spike protein immunoassay and surrogate viral neutralization tests (sVNT) against the Delta and Omicron (BA.1) variants. At 27.1 ± 3.2 days after the second dose, the antibody levels were 1476.6 ± 1185.4, 2999.4 ± 1725.9, and 4960.5 ± 2644.1 IU/mL in the LTRs, obese adolescents, and controls, respectively (p < 0.001). Among obese individuals, liver stiffness <5.5 kPa was associated with higher antibody levels. The %inhibition of sVNT was significantly lower for the Omicron than that for the Delta variant. Injection site pain was the most common local adverse event. Nine participants (three obese and six controls) developed COVID-19 at 49 ± 11 days after the second vaccination; four were treated with favipiravir. All infections were mild, and the patients recovered without any consequences. Our study supports the need for the booster regimen in groups with an inferior immunogenic response, including LTRs and obese individuals.
Open AccessImmunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants
There are limited data regarding the immunogenicity of mRNA-based SARS-CoV-2 vaccine BNT162b2 among immunosuppressed or obese adolescents. We evaluated the humoral immune response in adolescents with obesity and adolescent liver transplant recipients (LTRs) after receiving two BNT162b2 doses. Sixty-eight participants (44 males; mean age 14.9 ± 1.7 years), comprising 12 LTRs, 24 obese, and 32 healthy adolescents, were enrolled. Immunogenicity was evaluated by anti-SARS-CoV-2 spike protein immunoassay and surrogate viral neutralization tests (sVNT) against the Delta and Omicron (BA.1) variants. At 27.1 ± 3.2 days after the second dose, the antibody levels were 1476.6 ± 1185.4, 2999.4 ± 1725.9, and 4960.5 ± 2644.1 IU/mL in the LTRs, obese adolescents, and controls, respectively (p < 0.001). Among obese individuals, liver stiffness <5.5 kPa was associated with higher antibody levels. The %inhibition of sVNT was significantly lower for the Omicron than that for the Delta variant. Injection site pain was the most common local adverse event. Nine participants (three obese and six controls) developed COVID-19 at 49 ± 11 days after the second vaccination; four were treated with favipiravir. All infections were mild, and the patients recovered without any consequences. Our study supports the need for the booster regimen in groups with an inferior immunogenic response, including LTRs and obese individuals.
- Open Access
- 27 March 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 14 (3) , 583-591
Pediatric liver transplantation outcomes from a single center in Thailand
Pediatric liver transplantation outcomes from a single center in Thailand
- 27 March 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 14 (3) , 583-591
Open AccessPediatric liver transplantation outcomes from a single center in Thailand
Pediatric liver transplantation outcomes from a single center in Thailand
- Open Access
Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial
A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.
Open AccessSafety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial
A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.
- Open Access
- 7 July 2021
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 25 (7) , 812-816
Therapeutic Plasma Exchange with Continuous Renal Replacement Therapy for Pediatric Acute Liver Failure: A Case Series from Thailand
Pediatric acute liver failure (PALF) is a life-threatening condition. Extracorporeal support has been applied for toxic metabolite clearance and serves as a bridging therapy to liver transplantation (LT) or to the regeneration of the liver, but evidence for treatment approaches is still lacking in the pediatric population. We aim to report our experience on therapeutic plasma exchange with high-volume continuous renal replacement therapy (TPE + HV-CRRT) as a promising supportive treatment for PALF. A total of eight PALF cases aged 9 months to 14 years, weighing 10–50 kg., who were admitted to PICU King Chulalongkorn Memorial Hospital, Thailand and treated with TPE + HV-CRRT from January 2016 to September 2019 were reviewed. Patient demographic data, indications, technical aspects, and clinical outcomes were recorded. All patients who underwent TPE + HV-CRRT showed clinical improvement regarding serum bilirubin levels and coagulation studies after the therapy. Complications from the therapy were hemodynamic instability, symptomatic fluid overload, and bleeding from catheter sites. Among these, 6 (75%) patients survived with 4 (50%) successful LTs and 2 (25%) spontaneous recovery. Two children (25%) died while on the transplantation list. TPE + HV-CRRT can be used safely as a bridging therapy in children with PALF. As opposed to the adult population, higher volume of TPE or higher blood flow rate in pediatric patients might associate with hemodynamic instability during the procedure. Trepatchayakorn S, Chaijitraruch N, Chongsrisawat V, Chanakul A, Kongkiattikul L, Samransamruajkit R. Therapeutic Plasma Exchange with Continuous Renal Replacement Therapy for Pediatric Acute Liver Failure: A Case Series from Thailand. Indian J Crit Care Med 2021;25(7):812–816.
- 7 July 2021
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 25 (7) , 812-816
Open AccessTherapeutic Plasma Exchange with Continuous Renal Replacement Therapy for Pediatric Acute Liver Failure: A Case Series from Thailand
Pediatric acute liver failure (PALF) is a life-threatening condition. Extracorporeal support has been applied for toxic metabolite clearance and serves as a bridging therapy to liver transplantation (LT) or to the regeneration of the liver, but evidence for treatment approaches is still lacking in the pediatric population. We aim to report our experience on therapeutic plasma exchange with high-volume continuous renal replacement therapy (TPE + HV-CRRT) as a promising supportive treatment for PALF. A total of eight PALF cases aged 9 months to 14 years, weighing 10–50 kg., who were admitted to PICU King Chulalongkorn Memorial Hospital, Thailand and treated with TPE + HV-CRRT from January 2016 to September 2019 were reviewed. Patient demographic data, indications, technical aspects, and clinical outcomes were recorded. All patients who underwent TPE + HV-CRRT showed clinical improvement regarding serum bilirubin levels and coagulation studies after the therapy. Complications from the therapy were hemodynamic instability, symptomatic fluid overload, and bleeding from catheter sites. Among these, 6 (75%) patients survived with 4 (50%) successful LTs and 2 (25%) spontaneous recovery. Two children (25%) died while on the transplantation list. TPE + HV-CRRT can be used safely as a bridging therapy in children with PALF. As opposed to the adult population, higher volume of TPE or higher blood flow rate in pediatric patients might associate with hemodynamic instability during the procedure. Trepatchayakorn S, Chaijitraruch N, Chongsrisawat V, Chanakul A, Kongkiattikul L, Samransamruajkit R. Therapeutic Plasma Exchange with Continuous Renal Replacement Therapy for Pediatric Acute Liver Failure: A Case Series from Thailand. Indian J Crit Care Med 2021;25(7):812–816.